CorMedix Inc. (CRMD)
CorMedix Inc. (CRMD) from its SEC filings: 2025 revenue $311.7 million (+617% vs the year before), net margin 52%, free cash flow $172.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $311.7 million |
| Revenue growth | +617% |
| Net income | $163.1 million |
| Net margin | 52.3% |
| Free cash flow | $172.8 million |
| Diluted EPS | $2.04 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +156% |
| Cash | $256.7 million |
| Share count, 1 year | +4% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.